Orphazyme postpones 2021 annual report

Onlookers and shareholders who want to get their hands on the annual report from biotech firm Orphazyme, which has been besieged by bad news in recent times, will have to wait a little longer.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme predicts EU rejection after meeting with CHMP
For subscribers
Orphazyme CFO to take up CEO mantle ahead of time
For subscribers
Orphazyme stock plummets following bad news from CHMP
For subscribers